Cytokinetics reports positive Phase 1 data for CK-586; Phase 2 in HFpEF expected Q4 2024

CYTOKINETICS INC

Phase 1 study of CK-586 met primary safety, tolerability, PK objectives; no serious adverse events observed.
CK-586 is a novel cardiac myosin inhibitor for heart failure with preserved ejection fraction (HFpEF).
Phase 2 trial in HFpEF patients expected to begin in Q4 2024; based on Phase 1 safety and PK profile.
Echocardiography showed pharmacodynamics consistent with expectations; linear PK across doses 10-600 mg.
Aficamten, company's other cardiac myosin inhibitor, supported mechanism in non-obstructive HCM.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.